Elisabet de los Pinos, Aura Biosciences CEO
September 12, 2024 06:30 AM EDT
R&D

Au­ra's in­frared light-ac­ti­vat­ed drug stops tu­mor growth and pre­serves vi­sion in eight eye can­cer pa­tients

Lei Lei Wu

News Reporter

Au­ra Bio­sciences said eight of 10 pa­tients with a rare eye can­cer who re­ceived a ther­a­peu­tic dose of its ex­per­i­men­tal virus-like drug con­ju­gate saw their …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

A service from the Financial Times